21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      NMR as a “Gold Standard” Method in Drug Design and Discovery

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Studying disease models at the molecular level is vital for drug development in order to improve treatment and prevent a wide range of human pathologies. Microbial infections are still a major challenge because pathogens rapidly and continually evolve developing drug resistance. Cancer cells also change genetically, and current therapeutic techniques may be (or may become) ineffective in many cases. The pathology of many neurological diseases remains an enigma, and the exact etiology and underlying mechanisms are still largely unknown. Viral infections spread and develop much more quickly than does the corresponding research needed to prevent and combat these infections; the present and most relevant outbreak of SARS-CoV-2, which originated in Wuhan, China, illustrates the critical and immediate need to improve drug design and development techniques. Modern day drug discovery is a time-consuming, expensive process. Each new drug takes in excess of 10 years to develop and costs on average more than a billion US dollars. This demonstrates the need of a complete redesign or novel strategies. Nuclear Magnetic Resonance (NMR) has played a critical role in drug discovery ever since its introduction several decades ago. In just three decades, NMR has become a “gold standard” platform technology in medical and pharmacology studies. In this review, we present the major applications of NMR spectroscopy in medical drug discovery and development. The basic concepts, theories, and applications of the most commonly used NMR techniques are presented. We also summarize the advantages and limitations of the primary NMR methods in drug development.

          Related collections

          Most cited references447

          • Record: found
          • Abstract: not found
          • Article: not found

          Spin Diffusion Measurements: Spin Echoes in the Presence of a Time-Dependent Field Gradient

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Modified Spin-Echo Method for Measuring Nuclear Relaxation Times

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Principles of early drug discovery.

              Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development. © 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Molecules
                Molecules
                molecules
                Molecules
                MDPI
                1420-3049
                09 October 2020
                October 2020
                : 25
                : 20
                : 4597
                Affiliations
                [1 ]Core Labs, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia
                [2 ]Biological and Environmental Sciences & Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia; kacper.szczepski@ 123456kaust.edu.sa (K.S.); benjamingabriel.poulson@ 123456kaust.edu.sa (B.G.P.); kousik.chandra@ 123456kaust.edu.sa (K.C.); lukasz.jaremko@ 123456kaust.edu.sa (L.J.)
                [3 ]Department of Chemistry, University of Alberta, Edmonton, AB T6G 2W2, Canada; ryan.mckay@ 123456ualberta.ca
                [4 ]Biology Department, Faculty of Science, Taibah University, Yanbu El-Bahr 46423, Saudi Arabia; Manel.dhahri@ 123456gmail.com
                [5 ]Nanomedicine Department, Institute for Research and Medical, Consultations (IRMC), Imam Abdulrahman Bin Faisal University (IAU), Dammam 31441, Saudi Arabia; fsalahmari@ 123456iau.edu.sa
                [6 ]Department of Medical Sciences and Public Health, Università di Cagliari, Cittadella Universitaria, 09042 Monserrato, Italy
                Author notes
                [* ]Correspondence: abdelhamid.emwas@ 123456kaust.edu.sa (A.-H.E.); lachowicz@ 123456unica.it (J.I.L.); Mariusz.jaremko@ 123456kaust.edu.sa (M.J.); Tel.: +966-2-8084313 (A.-H.E.)
                Author information
                https://orcid.org/0000-0002-9231-3850
                https://orcid.org/0000-0001-8149-9023
                https://orcid.org/0000-0002-0255-159X
                https://orcid.org/0000-0003-4644-761X
                Article
                molecules-25-04597
                10.3390/molecules25204597
                7594251
                33050240
                38d73723-2246-4e5c-8bd1-581d3c690d24
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 22 September 2020
                : 06 October 2020
                Categories
                Review

                nmr,drug design,drug development,drug discovery,therapeutics

                Comments

                Comment on this article